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E. cob ihiorcdoxin plus thioredoxin reducla SP have previously been shown to rcplacc dithiothrcitol as ibe electron donor for mammalian liver 
microsomsl vihmin K epoxide reduction in vitro. Such activity is dependent on delcrpenl disruption of the rnicrosomul membrane integrity. A 
previously characterized salicylate-inhibhablc pathway for electron transfer from endogcnous cylosolic reducing a&cnls 10 the microsomal epoxide 
reducing warrarin-inhibitable cnzymc is no1 inhibited by known aliernate substrates and inhibitors of the thiorcdoxin system nor by amibodies 
against hioredoxin. 
Vitamil; K epoxidc rcductase; Thiorcdoxin; Thioredoxin rcductase; Salicylnte inhibition 
I. INTRODUCTION 
Thz metabolic transformations of vitamin K, hydro- 
quinonc to cpoxide and regeneration of the hydroqui- 
none via the quinone, and their relation to vitamin K- 
dependent protein synthesis have been well established 
[I]. The reactions of vitamin K epoxide and vitamin K 
quinonc reduction have been shown to be the sites of 
warfarin anticoagulant action. However, the physiolog- 
ically relevant reducing agent for these reaction, re- 
placed by dithiothreitol (DTT) in vitro, has not been 
identified. 
A salicylate-inhibitable pathway for the transfer of 
reducing equivalents from an endogenous cytosolic 
donor(s) to the epoxide-reducing, warfarin-inhibitable 
microsomal catalytic center has been demonstrated by 
Hildebrandt and Suttie [2]. Carlisle and Suttie [3] previ- 
ously demonstrated that the D-IT-dependent vitamin K 
epoxide reductase is located on the luminal surface of 
the rough endoplasmic reticulum (RER). An as yet ill- 
defined mechanism for transfer of reducing equivalents 
across the microsomal membrane, therefore, presuma- 
bly exists. 
Vermeer and coworkers [4] demonstrated that E. co/i 
thioredoxin plus its reductase could drive either vitamin 
K or vitamin K epoxide-dependent peptide (and pro- 
tein) carboxylation in partially purified solubilized mi- 
crosomal system. Similar results were apparently ob- 
tained with intact microsomes, but no data were pro- 
vided. 
Silverman and Nandi [S] demonstrated irectly by 
HPLC assay that E. coli thioredoxin plus its reductase 
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are capable of driving microsomal vitamin K epoxide 
reduction in both solubilized and intact rat and beef 
liver microsomes. As shown here, the results in intact 
microsomes are dependent on the concentration of de- 
tergent in which the vitamin is added, and thiorcdoxin 
is probably not the physiologically relevant reducing 
agent for this system in vivo. 
2. EXPERIMENTAL 
2.1. Prq7urariutts 
Whole rat liver microsomes and cylosol in 0.25 M sucrose, 0.01 M 
Tris-HCI, 1 mM EDTA. pH 7.6 buffer (Burer A) were prepared 
immediately before USC (within two hours) from perfused livers of 
freshly killed rats as previously described [6]. All assays were con- 
ducted in Buffer A at rocm temperature. 
2.2. dssap o/ ritioredoxitt-rftiorecloxin reducrusc and artri-rhiorcdoxitt 
Purified E, coli lhiorcdoxin oblained rrom Calbiochem was dis- 
solved in Buffer A to yield a stock solution of 5 m&ml (0.43 mM). 
Purified cystallinc E. cull thioredoxin reductase in ammonium sulfau 
suspension (American Diagnonica) was diluled with Bull-er A LO a 
concentration ofO.35 mdml(4.7yM). Bovine pancrealic insulin, 24.5 
iU/mg from Sigma was dissolved to yield a stock solulion of IO mgmL 
(I .B nlM). Activity of thioredoxin rcductase was assayed as insulin- 
dependent NADPH consumption monitored by absorbance nl 340 
nm, as described by Holmgren (7, and was round 10 be 3.6 pmol 
NADPH consume&minImg thioredoxin reductase. Under condhions 
where the concentralion ofthioredoxin was limiting, the specific acliv- 
ily of- the Calbiochem lhioredoxin was 0.426 Ecmol NADPH con- 
sumed/min/mg. Goat anti-E, cu/i lhioredoxin serum (American Dtg- 
nostica) was round to have a liter equivalent o 190 fig lhioredoxin 
neutralizing unils/ml serum based on inhibition of activity. 
The amount of rhioredoxin present in f’reshly prepared ral liver 
cytosol corresponded to a NADPH consumption rale cquivalcnl to 
0.18 mg/ml of E. cofi lhioredoxin. Aclivit,: was inhibhed 65% by 
addition of 20 yl anti-thioredoxin serum/O. I ml ofcytosol and almost 
completely by 40 ylI0.l ml or cytosol. 
2,3. ASSUJZ of viturttin K cposidc! reductase 
For assays of thioredoxindepcndcnl vittimin K epoxide reduction, 
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incubations containing 0.1 ml of microsomzs in Buffer A (equivalent 
lo 0.5 g liver/ml), 5~1 of I mM vilamin K cpoxidc in 1% Emulgen 91 I, 
plus or minus an additional 20 ~1 of I% Emulgen 911. 40 ~1 of 
thioredoxin (5 mg/ml). and 5Oyl of 20 mM NADPH, plus or minus 
inhibhor or vehicle, were assembled on ice in a total volume of02 ml 
of Buffer A. Following a two-minute lhermal equilibration lo room 
iempcraturc, the reaaions were initiated with IO ~1 of thioredoxin 
reductase (0.35 mdml) and incubated for IO min. No reaction was 
observed for the thiorcdoxin syslcm alone, or in the absence of any 
components of the compkc system. For assays of the dilhiokeitol- 
dependent reacticn, a I mM final concentration of DTT was used in 
place of the thiorcdoxin/rcduclasc~ADPH system. Addition of the 
complete thiorcdoxin system did not aller the activity observed with 
DTT alone. For assays ofcyrosol-dependent vitamin K epoxide reduc- 
lion, nliquots or 0.5 ml 0r microsomes (equivalent to I g liver/ml) 
resuspended in 0.5 g liver/ml of fresh cytosol, plus or minus the indi- 
cated inhibitors, were assembled on ice. Following a two-minute ther- 
mal equilibration, reactions were initialed by the addition of 5 ,kl of 
I mM vitamin K epoxide in I % Emulgcn 911 and incubated for 30 min 
at room temperalurc. In all cases, the reactions wcrc stopped by 
addition of 0.5 ml of 2 mM HgQ, extracted with 2 ml of isopropanoll 
heaane (I: I), and ihe amount of vitamin K formed quanlilated by 
reverse-phase HPLC with UV dcteclion. as previously described [Gl. 
3. RESULTS 
Initial attempts to reproduce the thioredoxin-depend- 
ent reduction of vitamin K cpoxide in whole micro- 
somes were unsuccessful. When the vitamin was added 
in a low final concentration of detergent (0.01% Emul- 
gen 911) as was customary in this laboratory, thiore- 
doxin-dependent reduction was almost negligible (Table 
I). When additional detergent was added to yield the 
appropriate final concentration used in the work of Sil- 
verman and Nandi [SJ, comparable rates of reduction 
were observed using either reductant. The decrease in 
the DTT-dependent rate at high detergent concentra- 
tion is typical of many detergents. 
Under conditions where thioredoxin-dependent vi a- 
min K epoxide reduction was significant (at 0.05% 
Emulgen 91 l), the reaction was no more sensitive to 
salicylate inhibition than was the DTT-dependent reac- 
tion. Inhibition at 200 ,uM salicylate was minimal 
(Table I). In contrast, when microsomal vitamin K ep- 
oxide reduction was assayed in the presence of freshly 
prepared cytosol as the source of reducing agent, the 
reaction was inhibited 60 percent by 200 ,uM salicylate 
Table I 
Vitamin K epoxide reduclion: cffecls of reductanl, detergent and sal- 
icylate” 
Reduclant 
Incubation condhions DTT Thioredoxin 
0.01% Emulgcn I .98 0.023 
0.05% Emulgen 0.42 0.43 
‘+ 200 flM Salicyke 0.35 0.35 
+ 1000 /rM Salicylate 0.21 0.18 
a nmol K formed/incubation. Average for duplicate incubationsdiffcr- 
ing by less than IO percent. Set section 2 for details. 
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(Table II). These results are consistent with a wcuk 
direct effect of salicylate on the microsomal vitamin K 
epoxide reducing center, itself, and suggest that thiorc- 
doxin, like DTT, bypasses the more sensitive salicylatc 
inhibitable site involved in the endogenous reductunt 
electron transfer pathway [2]. 
Table II compares the effects of various substrates 
and inhibitors on: (a) microsomal vitamin K epoxide 
reductase activity assayed using cytosol as the source of 
reducing equivalents, and (b) cytosolic thioredoxin sys- 
tem activity (assayed as insulin-dependent NADPH 
consumption). Salicylate inhibited vitamin K epoxide 
reduction but did not inhibit the cytosolic thioredoxin 
system. This was also confirmed for the purified E. co/i 
system components. Actinomycin (doxorubicin) and 
mitomycin [8] and NADP’ [9] inhibited the thioredoxin 
system by about 50 percent as expected from the refer- 
ences cited, but did not inhibit vitamin K epoxide reduc- 
tion, Insulin, a substrate for the thioredoxin system, did 
not inhibit cytosol dependent vitamin K epoxide reduc- 
tion as might be expected if both competed For limiting 
thioredoxin. Alloxan, a substrate for thioredoxin reduG:- 
tase [lo], did inhibit cytosol-dependent vi amin K epox- 
ide reduction (data not shown). However, alloxan also 
inhibited the DTT-dependent reaction and could be 
shown to titrate the amount of disulfide present, Fi- 
nally, and most significantly, goat anti& cofi thiore- 
doxin antiserum was shown to inhibit thioredoxin activ- 
ity in rat liver cytosol under conditions where it did not 
inhibit cytosol-dependent vi amin K epoxide reduction. 
4. DlSCUSSION 
Several lines of evidence suggest that both vitamin K 
epoxide reduction and vitamin K quinone reduction are 
catalyzed by the same microsomal enzyme [11,12] via a 
ping-pong kinetic mechanism [6,11], probably involving 
an active site disulfide [13]. Evidence suggests that 
coumarin anticoagulants, such as warfarin, act by 
blocking the reduction of the active site disulfide [13,14]. 
Table II 
Effects of inhibitors on cytosol-dependent microsomal vitamin K ep- 
oxide reduction and on the cylosolic lhioredoxin-thioredoxin reduc- 
lase system” 
Addition 
Salicylalc (200 PM) 
Actinomycin (100 /tM) 
Mitomycin (100 HIM) 
NADP’ (100 ph4) 
Insulin (I m@i?L) 
Anti-thioredoxin 
(40 ,ul/O. I ml cytosol) 
Epoxide Thioredoain 
reduction aclivily 
38 100 
9G 
107 ;: 
I02 34 
100 - 
91 G 
il Percent of control aclivilies: 0. I65 nmol vitamin K formed/incuba- 
tion and O.lB3 ALJlmin al 340 nm as described in section 2. Average 
of duplicuur differing by less than IO percent. 
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Previous work [2] has established a salicylate inhibitable 
pathway for the transfer of reducing equivalents from 
cytosol to the epoxide reducing center. This pathway is 
bypassed by dithiothreitol. The identity of the electron 
carriers in this pathway and the site of action of salicyl- 
ate (in addition to its weaker effect at a site not bypassed 
by DTT) remain to be determined. The evidence pre- 
sented here suggest hat the thioredoxin system is not 
part of this pathway. 
Disulfhydryl reagents, such as dithiothreitol, but not 
most other general or physiological reducing agents, are 
able to drive both the reduction of vitamin K epoxide 
and vitamin K quinone by liver microsomes [13]. Re- 
duced thioredoxin is able to act in this capacity [5] and 
the kinetic mechanism (ping pong) is the same as for 
dithiothreitol [G]. Mowever, the evidence presented here 
suggests that the thioredoxin-dependent reaction is not 
likely to be physiologically relevant. Thioredoxin is pre- 
dominantly a soluble cytoplasmic protein that also has 
some association with membranous tructures [ 15,161, 
however, clear evidence of its presence on the inside of 
the RER has not been presented. It is not apparent hat 
thioredoxin in intact cells would have access to the ep- 
oxide reducing enzyme which has been localized on the 
lumenal surface of intact RER membranes [3]. Further, 
the absence of a thioredoxin-dependent reaction at a 
low (0.01%) detergent concentration suggests that there 
is not a mechanism for transfer of reducing equivalents 
from this source across intact RER membranes. In the 
experiments of Vermeer and coworkers [4] on thiore- 
doxin plus vitamin K-or vitamin K epoxide-dependent 
carboxylation, the vitamin was apparently added in a 
mixture of phospholipid and sodium cholate. Conceiva- 
bly, the final level of cholate (non clearly stated) was 
sufficient o permeabilize the microsomal membranes of 
their ‘intact’ system enough to permit entry of thiore- 
doxin. 
Other thioredoxin like molecules are clearly RER res- 
ident proteins (i.e. protein disulfide isomerase [17] and 
ERp72 [IS]. Recently, Some, et al. [19] showed that 
purified protein disulfide isornerase stimulates thiore- 
doxin-dependent vitamin K-dependent carboxylase and 
vitamin K epoxide reductase activities in a solubilized 
microsomal preparation. This paper raised the interest- 
ing suggestion that protein sulfhydryl groups of nascent 
secretory proteins could provide a source of reducing 
equivalents for vitamin K epoxide and quinone reduc- 
tion. Further work is needed to test the thioredoxin 
requirement of this reaction (activity was tested with 
reduced RNAse as the reductant, in the presence of 
thioredoxin, plus protein disulfide isomerase, but not in 
the absence of thioredoxin) and to test the involvement 
of protein disulfide isomerase in intact membrane sys- 
tems and cells more closely resembling the situation 
in-vivo. 
Thioredoxin is known to be active in a variety of 
biochemical oxidation reduction reactions of physiolog- 
ical interest (e.g. the ribonucleotide reductase reaction) 
and in others as a useful but somewhat arbitrary reagent 
(e.g. in-vitro protein refolding). Regardless of its physi- 
ological relevance in vitamin K function, thioredoxin 
may be a useful reagent in the study of vitamin K epox- 
ide reductase (e.g., studies of inhibitors which are un- 
stable in the presence of excess thiol reagents). 
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